Seattle Genetics reports Adcetris data in CTCL

Seattle Genetics Inc. (NASDAQ:SGEN) said Adcetris brentuximab vedotin produced 12 partial responses and three cases of stable disease in 16 evaluable patients with relapsed CD30-positive cutaneous T cell lymphoma in an investigator-sponsored Phase II trial. Additionally, 68% of patients maintained response at week 25. Median duration of response has not yet been reached. The trial, which was sponsored by Stanford University, enrolled 17 patients with mycosis fungoides and Sezary syndrome, two forms of CTCL in which CD30 expression is variable. ...